Meeting
2015 ASCO Annual Meeting
Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).
Authors
Morie A. Gertz
Mayo Clinic, Rochester, MN
Morie A. Gertz , Martha Lacy , Angela Dispenzieri , Francis Buadi , David Dingli , Suzanne R. Hayman , Shaji Kumar , Nelson Leung , John Anthony Lust , S. Vincent Rajkumar , Stephen J. Russell , VeraJean Suman , William J. Hogan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Plasma Cell Disorders
Clinical Trial Registration Number
NCT00477971
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8595)
DOI
10.1200/jco.2015.33.15_suppl.8595
Abstract #
8595
Poster Bd #
414
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.
First Author: Robert F. Cornell
Poster
2021 ASCO Annual Meeting
LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).
First Author: Maria-Victoria Mateos
Poster
2020 ASCO Virtual Scientific Program
Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.
First Author: Iuliana Vaxman
Poster
2020 ASCO Virtual Scientific Program
Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.
First Author: Efstathios Kastritis